The board of directors of Hemfosa Fastigheter AB (publ) (“Hemfosa” or “the Company”) has, based on the issue authorisation granted by the annual general meeting on April 18, 2018, and as indicated in the Company’s press release earlier today, resolved on a directed share issue of 10 million common shares at a price of SEK 108.5 per share (the “Share Issue”), which means that the Company will receive proceeds of SEK 1,085 million before transaction costs. The price per share in the Share Issue was determined through an accelerated bookbuilding procedure.

The board of directors of Hemfosa concludes that the interest in the Share Issue was strong, as the communicated volume of up to 10 million common shares was oversubscribed by Swedish and international institutional investors shortly after the announcement of the Share Issue. The reasons for the deviation from the shareholders’ pre-emptive rights were to raise additional equity capital in a rapid and efficient manner to be able to exploit current business opportunities and to optimize the Company’s capital structure ahead of a planned split of the group. The additional equity capital improves the Company’s key performance indicators while enabling the Company to make further acquisitions of community service properties as well as other properties.

After the registration of the Share Issue, the total number of shares in the Company will amount to 178,728,248 (divided between 167,728,249 common shares and 10,999,999 preference shares). The Share Issue entails a dilution of approximately 5.6 per cent, based on the total amount of shares in Hemfosa after the Share Issue.

The new common shares will entitle to dividends once they have been entered into the share register kept by Euroclear Sweden, which is expected to take place on 25 June 2018. The next record date for dividend on the common shares will occur on July 10, 2018. In connection with the Share Issue, the Company has, under customary terms, undertaken to enter into a 90-day lock-up period as regards any future new issues.

In connection with the Share Issue the Company has engaged ABG Sundal Collier, SEB and Swedbank as Joint Lead Managers and Bookrunners and Advokatfirman Cederquist as legal counsel. Advokatfirman Vinge has acted as legal counsel to the Joint Lead Managers and Bookrunners.

Important information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Hemfosa in any jurisdiction.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to the United States, Canada, Australia, South Africa, Japan, Hong Kong, Switzerland, Singapore, New Zealand or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

This press release is not a prospectus. Hemfosa has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been prepared or will be prepared in connection with the directed new share issue. 

For more information, please contact:

Bengt Kjell, chairman of the board, cellphone 070-594 5398